5K SUNDAY MAY 15TH 2022

Registration is now open

NUROWN UPDATE

BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program

NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial.

NEWS

Lending a Helping Hand

PROMISING PATHWAY ACT

July 12, 2020

Take action to pass this bill

Take 30 seconds out of your day to help build Congress support